SynthesisAbdominal radiology (New York)2026
Prostatic artery embolization for palliative control of hematuria in locally advanced or metastatic prostate cancer: a systematic review.
Synthesis in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeProstatic artery embolization (PAE) has emerged as a minimally invasive option for the palliative control of hematuria in locally advanced or metastatic prostate cancer. This systematic review focuses on the efficacy and safety of PAE for this indication, while also synthesizing available data on secondary outcomes such as urinary retention and pain.
methodsA comprehensive search of PubMed/MEDLINE, Scopus, and Web of Science identified eight primary studies (four retrospective case series, one prospective cohort, and three case reports). Methodological quality was assessed using Joanna Briggs Institute (JBI) checklists and the Newcastle-Ottawa Scale (NOS).
resultsPAE demonstrated high technical success (89-100%) and immediate hemostatic control (67-100%), with durable symptom relief in most patients. Functional improvements in urinary retention (50-80% catheter-free rates) and pain (≈ 70% improvement) were observed, though outcomes varied. Major complications were rare (< 3%), supporting PAE's safety over traditional options like TURP (higher bleeding risk) or EBRT (delayed response).
conclusionPAE offers rapid, low-risk palliation for advanced prostate cancer symptoms. While it is a valuable alternative for high-risk patients, comparative trials are needed to define its role in obstruction and pain management.
Indexed as
Identifiers
41134363What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.